Table 2 TEAEs by baseline renal function and treatment arm.

From: Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

n (%)

eGFR <60 mL/min/1.73 m²

eGFR ≥60 mL/min/1.73 m²

Isa-Pd (n = 54)

Pd (n = 47)

Isa-Pd (n = 86)

Pd (n = 94)

Median treatment duration, weeks (range)

41.6 (4.0–74.1)

19.3 (1.0–65.0)

43.6 (3.1–76.7)

28.6 (1.7–73.7)

Any TEAE

54 (100.0)

47 (100.0)

85 (98.8)

91 (96.8)

Infectionsa

49 (90.7)

30 (63.8)

67 (77.9)

62 (66.0)

Cardiac disordersa

12 (22.2)

1 (2.1)

10 (11.6)

5 (5.3)

Gastrointestinal disordersa

30 (55.6)

28 (59.6)

46 (53.5)

44 (46.8)

General disorders and administration site conditionsa

29 (53.7)

32 (68.1)

45 (52.3)

53 (56.4)

Grade ≥3 TEAE

49 (90.7)

37 (78.7)

74 (86.0)

63 (67.0)

Infectionsa

30 (55.6)

18 (38.3)

33 (38.4)

27 (28.7)

Pneumoniab

14 (25.9)

11 (23.4)

11 (12.8)

12 (12.8)

Musculoskeletal disordersa

9 (16.7)

3 (6.4)

3 (3.5)

3 (3.2)

Grade 5 TEAE

5 (9.3)

6 (12.8)

3 (3.5)

6 (6.4)

Serious TEAE

42 (77.8)

28 (59.6)

44 (51.2)

48 (51.1)

TEAE leading to definitive treatment discontinuation

6 (11.1)

7 (14.9)

5 (5.8)

11 (11.7)

  1. eGFR estimated glomerular filtration rate, Isa isatuximab, Pd pomalidomide and dexamethasone, RI renal impairment, SOC system organ class, TEAE treatment-emergent adverse event.
  2. aSOC with TEAEs with an incidence ≥10% greater in patients with versus without RI in the same arm.
  3. bGrade ≥3 TEAE with an incidence ≥10% greater in patients with versus without RI in the same arm, among SOCs defined ina.
Back to article page